



## COMPANY OVERVIEW

Oragenics acquire assets related to proprietary neurological drug therapies, including a proprietary formulation and nasal delivery system. The assets include drug candidates for treating mild traumatic brain injury, also known as concussion, and for treating Niemann Pick Disease Type C.

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.

## RECENT NEWS

### Oragenics, Inc. Files 10K and Provides Company Update

Apr 1 2024, 9:05 AM EDT

## STOCK OVERVIEW

Symbol	OGEN
Exchange	NYSE American
Market Cap	5.47m
Last Price	\$1.22
52-Week Range	\$1.16 - \$7.74

04/15/2024 03:59 PM EDT

## INVESTOR RELATIONS

LHA Investor Relations  
Tirth T. Patel  
Vice President  
T: 212.201.6614  
[tpatel@lhai.com](mailto:tpatel@lhai.com)

## MANAGEMENT TEAM

**J. Michael Redmond**  
President & Interim Principal Executive Officer

**Janet Huffman**  
Chief Financial Officer

**Christine M. Farrell**  
Vice President of Finance

**James P. Kelly, MA, MD, FAAN, FANA**  
Chief Medical Officer

## ORAGENICS, INC.

4902 Eisenhower Blvd.  
Suite 125  
Tampa, FL 33634  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.